[go: up one dir, main page]

WO2003038032A3 - Produit inhibiteur de virus lents - Google Patents

Produit inhibiteur de virus lents Download PDF

Info

Publication number
WO2003038032A3
WO2003038032A3 PCT/DE2002/004052 DE0204052W WO03038032A3 WO 2003038032 A3 WO2003038032 A3 WO 2003038032A3 DE 0204052 W DE0204052 W DE 0204052W WO 03038032 A3 WO03038032 A3 WO 03038032A3
Authority
WO
WIPO (PCT)
Prior art keywords
vpr
hiv
immune deficiency
inhibitors
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2002/004052
Other languages
German (de)
English (en)
Other versions
WO2003038032A2 (fr
WO2003038032A8 (fr
Inventor
Hans Will
Uwe Tessmer
Karsten Bruns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE20220744U priority Critical patent/DE20220744U1/de
Priority to EP02782752A priority patent/EP1439853A2/fr
Priority to AU2002347102A priority patent/AU2002347102A1/en
Publication of WO2003038032A2 publication Critical patent/WO2003038032A2/fr
Publication of WO2003038032A8 publication Critical patent/WO2003038032A8/fr
Publication of WO2003038032A3 publication Critical patent/WO2003038032A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un produit destiné à l'inhibition de virus lents primates et notamment l'utilisation d'inhibiteurs de PPIase comme produit d'inhibition de virus de l'immunodéficience humaine de type 1 et 2 (HIV-1 et HIV-2) et de virus de l'immunodéficience simienne (SIV). A l'appui de la protéine virale R (Vpr), on démontre que les inhibiteurs de cis/trans peptidylprolyl-isomérases (PPIases) cellulaires inhibent l'expression, le pliage, la stabilité protéique tout comme l'efficacité biologique de Vpr. L'action anti-virale d'inhibiteurs de PPIase, plus particulièrement de Cyclosporine A, se fonde sur une interaction spécifique de PPIases, spécialement de cyclophiline A, avec des prolines sur le N-terminal de Vpr. Les domaines d'application sont la thérapie antirétrovirale et la prévention en cas d'infections par des virus lents provoqués par l'immunodéficience chez l'homme et les animaux, notamment de phénomènes pathologiques induits par AIDS ou HIV, également en combinaison avec d'autres médicaments anti-rétroviraux.
PCT/DE2002/004052 2001-10-25 2002-10-25 Produit inhibiteur de virus lents Ceased WO2003038032A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE20220744U DE20220744U1 (de) 2001-10-25 2002-10-25 Mittel zur Hemmung von Lentiviren
EP02782752A EP1439853A2 (fr) 2001-10-25 2002-10-25 Produit inhibiteur de virus lents
AU2002347102A AU2002347102A1 (en) 2001-10-25 2002-10-25 Means for inhibition of the synthesis of viral proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10153902.9 2001-10-25
DE10153902 2001-10-25

Publications (3)

Publication Number Publication Date
WO2003038032A2 WO2003038032A2 (fr) 2003-05-08
WO2003038032A8 WO2003038032A8 (fr) 2003-08-14
WO2003038032A3 true WO2003038032A3 (fr) 2003-10-30

Family

ID=7704423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/004052 Ceased WO2003038032A2 (fr) 2001-10-25 2002-10-25 Produit inhibiteur de virus lents

Country Status (4)

Country Link
EP (1) EP1439853A2 (fr)
AU (1) AU2002347102A1 (fr)
DE (1) DE20220744U1 (fr)
WO (1) WO2003038032A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361944A1 (de) * 2003-12-31 2005-07-28 Viromics Gmbh Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281A2 (fr) * 1990-11-02 1992-05-06 Sandoz Ltd. Cyclosporines
WO1997033604A1 (fr) * 1996-03-12 1997-09-18 Picower Institute For Medical Research Traitement de l'infection a vih par action sur le recepteur de la cyclophiline de cellules hotes
WO2003038056A2 (fr) * 2001-11-02 2003-05-08 The Regents Of The University Of California Methodes permettant d'inhiber la replication d'un lentivirus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281A2 (fr) * 1990-11-02 1992-05-06 Sandoz Ltd. Cyclosporines
WO1997033604A1 (fr) * 1996-03-12 1997-09-18 Picower Institute For Medical Research Traitement de l'infection a vih par action sur le recepteur de la cyclophiline de cellules hotes
WO2003038056A2 (fr) * 2001-11-02 2003-05-08 The Regents Of The University Of California Methodes permettant d'inhiber la replication d'un lentivirus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRIGGS C J ET AL: "Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV -1.", ARCHIVES OF VIROLOGY, (1999) 144 (11) 2151-60., XP000993073 *
HUSS, RALF: "Inhibition of cyclophilin function in HIV -I infection by cyclosporin A", IMMUNOLOGY TODAY (1996), 17(6), 259-260, XP004034608 *
MINDER D ET AL: "Immunophilins and HIV -1 infection.", ARCHIVES OF VIROLOGY, (2002 AUG) 147 (8) 1531-42., XP002251068 *
MLYNAR E ET AL: "The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells.", THE JOURNAL OF GENERAL VIROLOGY. ENGLAND APR 1997, vol. 78 ( Pt 4), April 1997 (1997-04-01), pages 825 - 835, XP002251070, ISSN: 0022-1317 *
STEINKASSERER A ET AL: "Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 ( HIV -1): interference with early and late events in HIV -1 replication.", JOURNAL OF VIROLOGY, (1995 FEB) 69 (2) 814-24., XP002251069 *
STREBLOW D N ET AL: "Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A.", VIROLOGY, (1998 JUN 5) 245 (2) 197-202., XP002251067 *

Also Published As

Publication number Publication date
EP1439853A2 (fr) 2004-07-28
WO2003038032A2 (fr) 2003-05-08
DE20220744U1 (de) 2004-05-13
WO2003038032A8 (fr) 2003-08-14
AU2002347102A1 (en) 2003-05-12

Similar Documents

Publication Publication Date Title
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
EA200200724A1 (ru) Вакцина для профилактической или терапевтической иммунизации против вируса иммунодефицита человека (вич)
CA2217737A1 (fr) Sulfamides contenant tetrahydrofurane (thf) et agissant comme inhibiteurs de la protease aspartyle
AP1717A (en) Sulfonamide inhibitors of aspartyl protease.
WO2004096818A3 (fr) Procede et compositions pour l'identification de composes therapeutiques anti-vih
TW200510425A (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
MY115797A (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
BR9607625A (pt) Inibidores de protease retroviral sulfonamida hidroxietilamino de aminoácido heterociclocarbonila
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
EP1637518A3 (fr) Inhibiteurs de la protéase d'aspartyle
WO2004029201A3 (fr) Inhibiteurs de fusion contre l'infection au vih derives de peptides
WO2003038032A3 (fr) Produit inhibiteur de virus lents
ATE374208T1 (de) Pharmakologisch aktive antivirale peptide und methoden zu ihrer anwendung
CA2195125A1 (fr) Agents antiviraux a base de difluorostatone
GR3024226T3 (en) Antiviral naphthoquinone compounds, compositions and uses thereof.
WO2022125378A8 (fr) Polythérapie
WO2007002172A3 (fr) Inhibiteurs de la protease du vih-1
WO2002064154A3 (fr) Techniques et compositions permettant d'inhiber les interactions du corecepteur du vih
MXPA04004061A (es) Derivados de quinolina y piridina antiretrovirales.
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
WO2002034909A3 (fr) Chimere de fragments de proteines synthetisee et ses methodes d'utilisation
DK0545991T3 (da) Peptider, der blokerer infektioner med human immundefektvirus, og fremgangsmåder til anvendelse deraf
AP2003002852A0 (en) Natural antibodies active against HIV virus
WO2003104262A3 (fr) Peptides de gp41 et methodes faisant appel a ces peptides pour inhiber une fusion du vih avec des cellules cibles
GB2382529A (en) Immunomodulator for the management of human immunodficiency virus (hiv) disease/infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 19/2003 UNDER (72) DELETE ""SCHUBERT, ULRICH; JENAISCHE STRASSE 51, 07407 UHLSTAEDT (DE).""

WWE Wipo information: entry into national phase

Ref document number: 2002782752

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002782752

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP